Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

Abstract

Peripheral T-cell lymphoma is a heterogenous non-Hodgkin Lymphoma with historically poor outcomes. Currently, response rates remain poor with traditional chemotherapy and many of those responding to initial therapy will relapse. Belinostat (Beleodaq, Spectrum Pharmaceuticals) is a histone deacetylase inhibitor (HDACi) approved for use in relapsed or refractory peripheral T-cell lymphoma (PTCL). Belinostat is metabolized hepatically through cytochrome P-450 enzymes 3A4, 2C9, and 2A6; however, no empiric dosage adjustments of belinostat are recommended during concurrent use of inhibitors or inducers of these enzymes. Belinostat’s efficacy has been evaluated in a clinical trial showing an overall response rate (ORR) of 25.8% and a median duration of response of 8.4 months. Belinostat is generally well tolerated, with the most common adverse reactions (>25%) being nausea, vomiting, fatigue, pyrexia, and anemia in patients with relapsed or refractory PTCL. Belinostat is a safe and effective treatment option for relapsed and refractory peripheral T-cell lymphoma, with many future applications currently being investigated.

Keywords

Hematology oncology lymphoma

Get full access to this article

View all access options for this article.

References

Swerdlow

Campo

Harris

. WHO classification of tumours of haematopoietic and lymphoid tissues, Lyon, France: International Agency for Research on Cancer, 2008.

Mak

Hamm

Chhanabhai

. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors. J Clin Oncol 2013; 31: 1970–1976.

Coffier

Federico

Caballero

. Therapeutic options for relapsed or refractory peripheral T-cell lymphoma. Cancer Treat Rev 2014; 40: 1080–1088.

Corradini

Tarella

Zallio

. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533–1538.

Rodríguez

Conde

Gutiérrez

. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007; 79: 32–38.

Thompson

. Belinostat approved for use in treating rare lymphoma. Am J Health Syst Pharm 2014; 71: 1328–1328.

Poole

. Belinostat: First global approval. Drugs 2014; 74: 1543–1554.

Beleodaq (Belinostat) package insert. Irvine, CA: Spectrum Pharmaceuticals, 2014.

Ropero

Esteller

. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1: 19–25.

10.

SOLVO-TopoTarget-01. In vitro interaction studies of one test article with P-gp (MDR1/ABCB1) in the vesicular transport assay and in Bidirectional Transport (Papp) Studies on Caco-2 monolayers. Internal report 2010.

11.

Foss

Advani

Duvic

. A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 2015; 168: 811–819.

12.

Reimer

Chawla

. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma. J Hematol Oncol 2013; 6: 69–69.

13.

Brentuximab vedotin (Adcetris) package insert. Bothell, WA: Seattle Genetics, 2015.

14.

Pralatrexate (Folotyn) package insert. Westminster, CO: Allos Therapeutics, 2011.

15.

Furumai

Matsuyama

Kobashi

. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2012; 62: 4916–4921.

16.

Gryder

Sodji

Oyelere

. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012; 4: 505–524.

17.

Lane

Chabner

. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459–5468.

18.

Miller

Witter

Belvedere

. Histone deacetylase inhibitors. J Med Chem 2003; 46: 5097–5116.

19.

National Comprehensive Cancer Network. Non-Hodgkin lymphoma (Version 2.2015). http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (accessed 12 April 2015).

20.

ClinicalTrials.gov. Belinostat. http://clinicaltrials.gov/ct2/results?term=belinostat&Search=Search (accessed 13 April 2015).

21.

Chun P. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res 2015. Epub ahead of print.

22.

Tula-Sanchez

Havas

Alonge

. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Cancer Biol Ther 2013; 14: 949–961.

23.

Kaufman

Fabre

Lonial

. Histone deactylase inhibitors in multiple myeloma: Rationale and evidence for their use in combination therapy. Clin Lymphoma Myeloma Leuk 2013; 13: 370–376.

24.

Kirschbaum

Foon

Frankel

. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: A California Cancer Consortium Study. Leuk Lymphoma 2014; 55: 2301–2304.

25.

Savickiene

Treigyte

Valiuliene

. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells. Anticancer Drugs 2014; 25: 938–949.

26.

Lin

Chou

. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS One 2013; 8: e77684–e77684.

27.

Hainsworth JD, Daugaard G, Lesimple T, et al. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. Cancer 2015. Epub ahead of print.

28.

Kim MJ, Lee JS, Park SE, et al. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: A role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase. J Urol 2014. Epub ahead of print.

29.

Thomas

Rajan

Szabo

. A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: A clinical and translational study. Clin Cancer Res 2014; 20: 5392–5402.

30.

Dizon

Blessing

Penson

. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 367–371.